Successful Allogeneic Hematopoietic Stem Cell Transplantation From A 5/10 Mismatched Unrelated Donor in A Patient With Donor-specific Anti-hla Antibodies.

[1]  R. Varadhan,et al.  Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. , 2017, Blood.

[2]  G. Rosner,et al.  Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. , 2017, Blood advances.

[3]  A. Santoro,et al.  Desensitization with plasma exchange in a patient with human leukocyte antigen donor‐specific antibodies before T‐cell–replete haploidentical transplantation , 2016, Transfusion.

[4]  J. Esteve,et al.  Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness , 2015, Platelets.

[5]  J. Esteve,et al.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.

[6]  A. Zachary,et al.  Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  H. Ogawa,et al.  The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA? , 2012, Bone Marrow Transplantation.

[8]  T. Haferlach,et al.  Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia , 2011, Leukemia.

[9]  J. Klein,et al.  The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. , 2007, Blood.

[10]  E. Shpall,et al.  High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem Cell Transplantation , 2009 .

[11]  J. Serody,et al.  Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. , 2007, Blood.